Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II: Multicenter, Open, Dose-escalation Evaluation of the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B Treated With Oral Antiviral Therapy(Long-term Follow-up)

NCT05760703 is registered in ClinicalTrials.gov with Staidson (Beijing) Biopharmaceuticals Co., Ltd as lead sponsor.

NCT NCT05760703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05760703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II: Multicenter, Open, Dose-escalation Evaluation of the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B Treated With Oral Antiviral Therapy(Long-term Follow-up)
Lead sponsor
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase
Phase 2
Overall status
Terminated
Start date
April 25, 2023
Completion date
December 11, 2023
Enrollment
9 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b